By Nana O 
An experimental drug currently undergoing clinical trials as a cancer treatment has demonstrated significant potential to augment first-line tuberculosis (TB) therapies by promoting a gentler form of cell death in infected cells, according to groundbreaking research from Johns Hopkins Medicine investigators. The findings, derived from extensive mouse-model studies of the lung-damaging disease, offer a beacon of hope for developing more effective and less debilitating treatments that can substantially reduce lung damage in TB survivors. This innovative approach could also be crucial in preventing the long-term lung dysfunction, increasingly recognized as post-TB lung disease, which affects an estimated tens of millions of individuals globally. The study, generously funded by the National Institutes of Health and published on March 27 in the prestigious journal Nature Communications, marks a pivotal advancement in the ongoing battle against this persistent global health threat.
The Urgent Need for Novel TB Therapies
Tuberculosis, a curable and preventable disease, has regrettably re-emerged as a leading cause of death worldwide. The World Health Organization (WHO) reported an estimated 1.25 million deaths and 10.8 million new cases in 2023 alone, underscoring the escalating urgency to find more potent treatment strategies. Compounding this crisis is the growing prevalence of drug-resistant TB strains, which render the gold-standard antibiotic treatments less effective and significantly complicate patient recovery. Current TB treatment regimens are notoriously lengthy, often spanning six months or more, are expensive, and frequently leave patients vulnerable to relapse and the development of irreversible lung scarring.
"Current treatment regimens for TB are lengthy, expensive and leave patients vulnerable to relapse and lung scarring," stated Dr. Sanjay Jain, the study’s senior author, a distinguished pediatric infectious diseases specialist at Johns Hopkins Children’s Center and professor of pediatrics at the Johns Hopkins University School of Medicine. "Our research shows that adding in a host-directed therapy has extraordinary promise to solve these problems."
Understanding Tuberculosis and Cell Death Pathways
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis (Mtb). In the early stages of infection, the body’s infected lung cells attempt to contain the spread of the pathogen through a process called apoptosis. Apoptosis, often referred to as programmed cell death, is a tightly regulated and controlled molecular mechanism that effectively self-destructs infected cells, thereby limiting the pathogen’s ability to proliferate.
However, as TB infection progresses into later stages, the dynamics shift dramatically. The uncontrolled proliferation of Mtb leads to a different, far more destructive form of cell death known as necrosis. Unlike the orderly demolition of apoptosis, necrosis is characterized by the uncontrolled rupture of cells, releasing inflammatory molecules and damaging surrounding healthy tissue. Dr. Jain vividly compares apoptosis to the controlled demolition of a building, ensuring minimal collateral damage, while necrosis is akin to a bomb explosion, causing widespread devastation.
The Bacterial Subterfuge: Hijacking Cell Death for Survival
The insidious nature of Mtb lies in its ability to manipulate host cell processes to its advantage. The bacterium achieves this by prompting infected "host cells" to overproduce Bcl-2, a crucial family of anti-apoptotic proteins. By inducing the host cell to resist its own programmed death, Mtb effectively creates a safe haven for its replication.
"This hijack of a typically healthy molecular pathway has significant advantages for M. tuberculosis," explained Dr. Medha Singh, the study’s first author and a pediatric infectious diseases fellow at the Johns Hopkins University School of Medicine. "It promotes necrotic niches within the lung that prevent immune system attacks and allow the bacteria to multiply." This manipulation of the host’s apoptotic machinery provides Mtb with a critical survival advantage, enabling it to evade immune surveillance and establish a persistent infection.
A Novel Therapeutic Strategy: Targeting Host Cells, Not Just Bacteria
While previous research had explored the concept of inhibiting Bcl-2 as a potential strategy to combat TB, these efforts had largely focused on direct antimicrobial approaches. The groundbreaking aspect of the current study is its exploration of a "host-directed therapy"—an intervention aimed at modulating the infected host cells rather than directly targeting the infectious bacteria. This approach holds the promise of overcoming the challenges posed by antibiotic resistance.
"Although previous research has suggested inhibiting Bcl-2 as a strategy to fight TB, this host-directed therapy — aimed at infected host cells, rather than the infective bacteria — had never been tested using a real-world TB treatment," Dr. Singh noted.
The Experimental Design and Promising Results
To rigorously test this novel therapeutic concept, the Johns Hopkins researchers designed a comprehensive study involving mice infected with Mtb. The experimental group of mice received the standard first-line TB treatment regimen, consisting of the antibiotics rifampin, isoniazid, and pyrazinamide (collectively known as RHZ). Crucially, a subset of these mice also received navitoclax, a potent Bcl-2 inhibitor. Navitoclax is already under investigation in clinical trials for its efficacy in treating various cancers by accelerating programmed cell death.
The results of this carefully controlled experiment were striking. When compared to mice treated with RHZ alone, those that received the combination therapy of RHZ and navitoclax exhibited a remarkable 40% reduction in necrotic lesions within their lungs. Furthermore, the spread of the infection to other vital organs, such as the spleen, was significantly curtailed over the four-week treatment period.
Advanced Imaging Reveals Profound Benefits
The study’s impact was further amplified by the use of advanced imaging technologies. Leveraging clinically translatable positron emission tomography (PET) technologies, the researchers were able to visualize and quantify apoptosis and fibrosis in live animals. These sophisticated imaging techniques revealed that the addition of navitoclax to the standard RHZ treatment not only doubled the amount of pulmonary apoptosis but also led to a substantial 40% reduction in lung scarring.
"Imaging in live animals using clinically translatable positron emission tomography (PET) technologies for apoptosis and fibrosis showed that the addition of navitoclax doubled the amount of pulmonary apoptosis and reduced lung scarring by 40% compared to standard TB treatments alone," reported Dr. Laurence Carroll, a study author and assistant professor of radiology at the Johns Hopkins University School of Medicine.
Perhaps most compellingly, while navitoclax alone had no discernible effect on Mtb bacterial burden, the mice treated with both navitoclax and RHZ demonstrated a dramatically enhanced ability to clear the infection. Their bacterial burden decreased an astonishing 16 times more effectively than in mice receiving RHZ alone. This synergistic effect highlights the power of combining host-directed therapy with conventional antimicrobial treatment.
Implications for Global Health and Future Research
The implications of these findings extend far beyond tuberculosis. Dr. Jain believes that navitoclax could offer similar benefits for patients suffering from other chronic bacterial infections, including those caused by Staphylococcus aureus and non-TB mycobacteria, which are highly prevalent in the United States.
"These results suggest that navitoclax could offer similar effects for TB patients as well as patients with other chronic bacterial infections, such as Staphylococcus aureus and non-TB mycobacteria highly prevalent in the U.S.," Dr. Jain stated.
The path forward necessitates rigorous clinical trials to validate these promising findings in human patients. Dr. Jain emphasized the critical role of innovative imaging approaches, such as those developed at the Johns Hopkins Center for Infection and Inflammation Imaging Research, where he serves as director. These advanced PET imaging techniques could provide early indicators of the host-directed therapy’s effectiveness and offer precise visualization of lung scarring, crucial for monitoring treatment progress and outcomes.
If successful, these clinical trials could pave the way for the integration of navitoclax or similar drugs into the standard antibiotic regimen for TB. Such a therapeutic paradigm shift could lead to several significant improvements:
- Shorter Treatment Durations: The ability to enhance bacterial clearance and reduce inflammation might allow for a reduction in the lengthy six-month course of daily treatment, thereby improving patient adherence and reducing the overall burden of care.
- Reduced Lung Scarring and Post-TB Lung Disease: By promoting gentler cell death and mitigating uncontrolled inflammation, this approach could significantly decrease the incidence and severity of lung scarring, a debilitating long-term consequence of TB infection. This would directly address the growing concern of post-TB lung disease, which can lead to chronic respiratory issues and reduced quality of life for millions.
- Improved Outcomes for Drug-Resistant TB: For patients with drug-resistant strains of TB, where treatment options are limited and outcomes are often poor, this host-directed therapy could offer a vital new avenue for more effective management and improved survival rates.
Collaborative Efforts and Funding
This pivotal research was a collaborative effort involving a dedicated team of scientists at Johns Hopkins. The study was supported by substantial funding from the National Institutes of Health through several grants, including R01-AI153349, R01-AI145435-A1, R56-AI179012-A1, R01-AI190038, and S10-OD030381-A1. Importantly, no authors declared any conflicts of interest under the Johns Hopkins University School of Medicine policies, ensuring the integrity and objectivity of the research.
The researchers involved in this study include Mona Sarhan, Nerketa Damiba, Alok Singh, Andres Villabona-Rueda, Oscar Nino-Meza, Xueyi Chen, Yuderleys Masias-Leon, Carlos Ruiz-Gonzalez, Alvaro Ordonez, and Franco D’Alessio, all from Johns Hopkins. Their collective expertise and dedication have been instrumental in advancing this critical area of medical research.
A Glimpse into the Future of Infectious Disease Treatment
The findings from this mouse-model study represent a significant leap forward in our understanding of how to combat tuberculosis and other chronic bacterial infections. By shifting the therapeutic focus to modulating the host’s response, researchers are opening up new possibilities for treatments that are not only more effective but also gentler on the patient, ultimately aiming to improve long-term health outcomes and reduce the lasting impact of these devastating diseases. The journey from laboratory discovery to widespread clinical application is often long and complex, but the promise shown by this experimental drug offers a compelling vision for the future of infectious disease management.
